Terns TERN 深 沪
交易中 05-11 11:52:30 美东时间
52.967
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 52.967
- 总市值 133.90万
- 52周最高 53.19
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.82
- 委 比 0.00%
- 总股本 2.53万
- 历史最高 53.19
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.10
- 每 手 1
- 风险率 18.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Terns Pharmaceuticals Wins FDA Breakthrough Therapy Designation For TERN-701 In Resistant CML
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to
04-27 20:13
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
04-23 02:20
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition and CML treatment comparisons.
04-08 02:28
Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs
Infinimmune, Merck ink deal to develop human-derived antibodies using the Anthrobody platform. See the full agreement details.
04-01 21:26
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiry.
03-25 17:38
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.
2025-12-09 20:51
Terns Pharma Plans $400M Stock Offering To Fund Cancer Drug Development
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its
2025-12-09 19:20
William Blair Upgrades Terns Pharma to Outperform
William Blair analyst Andy Hsieh upgrades Terns Pharma (NASDAQ:TERN) from Market Perform to Outperform.
2025-11-04 05:24
减重降糖赛道深度研究丨开源证券医药
（来源：开源证券研究所） 减重降糖赛道一直是近年来最受关注的创新药研发领域之一，以司美格鲁肽、替尔泊肽为代表的GLP-1受体激动剂类药物正在彻底改变肥胖...
2025-09-18 08:01
开源证券：Orforglipron领跑全球小分子GLP-1RA赛道 国内管线价值逐渐凸显
开源证券发布研报称，小分子GLP-1RA有望为减重降糖市场提供新的增量空间。礼来的Orforglipron是全球进度最快的小分子GLP-1RA产品，目前针对多个...
2025-09-03 09:34
